FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023795211> ?p ?o ?g. }

• W2023795211 endingPage "305" @default.
• W2023795211 startingPage "305" @default.
• W2023795211 abstract "Sir, A 24 year old female, doctor by profession self medicated herself with tablet ciprofloxacin 500 mg BD for 5 days after she was diagnosed to have severe gastroenteritis. Two days later, she reported nightmares which continued for four consecutive days. On history taking, she could remember two of the frightful experiences that she dreamt of. In one of the dreams, she visualized a lady - whom she had never seen before - who, after calling two girls to her place, brutally assaulted them, slaughtered them by cutting their throats with a knife and crucified them alive. In another dream, she saw herself stranded in a dilapidated haunted house with strange and supernatural things happening around her. Every time she used to get up with sweating, palpitations, fear, anxiousness, and nervousness. She was irritable and experienced mood changes, while on therapy. The dreams subsided spontaneously after a day of completing her course for 5 days. Causality assessment score by Naranjo Algorithm was 9, putting it in a “highly probable” Adverse Drug Reaction (ADR) category. Fluoroquinolones are one of the most commonly prescribed antibiotics for urinary tract infections and gastroenteritis and exhibit broad spectrum antimicrobial spectrum. Fluoroquinolones have always been under controversy due to their serious ADR profile. Temafloxacin and grepafloxacin are already withdrawn from the US market as a result of reported multi system toxicity and torsades de pointes cases, respectively, sparfloxacin for its quinolone toxicity (QT) prolongation and phototoxicity, trovafloxacin has been forbidden in Europe and United Kingdom due to several deaths reported caused by hepatic toxicity and off late Bristol-Myers Squibb Co. announced the withdrawal of their brand of gatifloxacin (Tequin) due to dysglycaemia reported in many patients.[1] Permanent neurological, visual, and musculoskeletal damage has been reported in many patients taking this particular group of antibiotic and most of them are unaware that their illness is a manifestation of QT. Central Nervous System (CNS) ADRs of fluoroquinolones are well documented. These ADRs can range from patients getting mild confusion to acute psychosis.[2] Rataboli et al. reported an unusual hallucination with norfloxacin.[3] The case histories at times can be so perplexing that the doctors refer such patients to the psychiatrists as it is difficult to believe that it could be a drug reaction as well. The exact pathology of CNS effects is still not understood but one of the hypotheses suggests the stimulatory effect of quinolones to drug interactions with the Gamma-Amino Butyric Acid receptor (GABA), an inhibitory neurotransmitter, and direct activation of N-methyl-D-aspartate (NMDA) and adenosine receptor mechanisms. Sleep disorders are very rare, but recognized adverse events with fluoroquinolones.[4] Couple of case reports have been published in the past showing fluroquinolone therapy causing agitated sleepwalking and nightmares particularly in the paediatric age group.[5] An episode like the one we report in an adult is very rare and merits a mention. Nightmares are defined as nocturnal episodes of intense anxiety and fear associated with a vivid, emotionally charged dream experience and is generally classified as parasomnia. Several possible pharmacologic mechanisms for drug-induced nightmares have been proposed as mentioned above. However, the vast majority of therapeutic agents implicated in causing nightmares have no obvious pharmacologic mechanism. Even assessing the causality with such an event is a difficult task because of the high incidence of nightmares in the healthy population as well. In our case, the causality assessment of this ADR was relatively simpler because the nightmares lasted for four days throughout the duration of therapy and disappeared at the end of the course. One of the reviews published showed sedatives/hypnotics, beta-blockers and amphetamines as the most common therapeutic modalities associated with nightmares.[6] Australian ADR bulletin reported many suspected cases of drug induced nightmares with SSRIs, benzodiazepines and statins.[7] Hence, we conclude that prescribers especially psychiatrists should be aware of the fact that there are many such drugs that may cause nightmares and other CNS symptoms, which they may mistakenly diagnose as some psychiatric illness. Taking proper history of drug intake may become an important tool to diagnose the same in such a rare scenario." @default.
• W2023795211 created "2016-06-24" @default.
• W2023795211 creator A5013065378 @default.
• W2023795211 creator A5042572650 @default.
• W2023795211 creator A5053459859 @default.
• W2023795211 date "2008-01-01" @default.
• W2023795211 modified "2023-10-18" @default.
• W2023795211 title "Ciprofloxacin induced nightmares in an adult patient" @default.
• W2023795211 doi "https://doi.org/10.4103/0019-5545.44757" @default.
• W2023795211 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2755150" @default.
• W2023795211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19823620" @default.
• W2023795211 hasPublicationYear "2008" @default.
• W2023795211 type Work @default.
• W2023795211 sameAs 2023795211 @default.
• W2023795211 citedByCount "6" @default.
• W2023795211 countsByYear W20237952112012 @default.
• W2023795211 countsByYear W20237952112015 @default.
• W2023795211 countsByYear W20237952112018 @default.
• W2023795211 countsByYear W20237952112019 @default.
• W2023795211 countsByYear W20237952112022 @default.
• W2023795211 countsByYear W20237952112023 @default.
• W2023795211 crossrefType "journal-article" @default.
• W2023795211 hasAuthorship W2023795211A5013065378 @default.
• W2023795211 hasAuthorship W2023795211A5042572650 @default.
• W2023795211 hasAuthorship W2023795211A5053459859 @default.
• W2023795211 hasBestOaLocation W20237952111 @default.
• W2023795211 hasConcept C118552586 @default.
• W2023795211 hasConcept C2776072828 @default.
• W2023795211 hasConcept C2778512257 @default.
• W2023795211 hasConcept C2778746504 @default.
• W2023795211 hasConcept C501593827 @default.
• W2023795211 hasConcept C71924100 @default.
• W2023795211 hasConcept C86803240 @default.
• W2023795211 hasConcept C89423630 @default.
• W2023795211 hasConceptScore W2023795211C118552586 @default.
• W2023795211 hasConceptScore W2023795211C2776072828 @default.
• W2023795211 hasConceptScore W2023795211C2778512257 @default.
• W2023795211 hasConceptScore W2023795211C2778746504 @default.
• W2023795211 hasConceptScore W2023795211C501593827 @default.
• W2023795211 hasConceptScore W2023795211C71924100 @default.
• W2023795211 hasConceptScore W2023795211C86803240 @default.
• W2023795211 hasConceptScore W2023795211C89423630 @default.
• W2023795211 hasIssue "4" @default.
• W2023795211 hasLocation W20237952111 @default.
• W2023795211 hasLocation W20237952112 @default.
• W2023795211 hasLocation W20237952113 @default.
• W2023795211 hasLocation W20237952114 @default.
• W2023795211 hasOpenAccess W2023795211 @default.
• W2023795211 hasPrimaryLocation W20237952111 @default.
• W2023795211 hasRelatedWork W1939845724 @default.
• W2023795211 hasRelatedWork W1980145572 @default.
• W2023795211 hasRelatedWork W1992163602 @default.
• W2023795211 hasRelatedWork W2062191794 @default.
• W2023795211 hasRelatedWork W2102998848 @default.
• W2023795211 hasRelatedWork W2147575544 @default.
• W2023795211 hasRelatedWork W2169103588 @default.
• W2023795211 hasRelatedWork W2473904300 @default.
• W2023795211 hasRelatedWork W37262651 @default.
• W2023795211 hasRelatedWork W4241563807 @default.
• W2023795211 hasVolume "50" @default.
• W2023795211 isParatext "false" @default.
• W2023795211 isRetracted "false" @default.
• W2023795211 magId "2023795211" @default.
• W2023795211 workType "article" @default.